Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03QIE
|
|||
Former ID |
DCL000723
|
|||
Drug Name |
Bicifadine
|
|||
Synonyms |
BICIFADINE; 71195-57-8; 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane; 1-p-tolyl-3-azabicyclo[3.1.0]hexane; 5-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-; CL-220075; PubChem18323; AC1L2J2O; SCHEMBL38793; AZA001; CHEMBL511099; OFYVIGTWSQPCLF-UHFFFAOYSA-N; NIH-9542; MCV-4147; BDBM50417944; AKOS006271730; DOV-220075; AN-3206; DB04889; KB-13207; 5-(p-tolyl)-3-azabicyclo[3.1.0]hexane; AM20041063; FT-0718156; 1-(p-tolyl)-3-azabicyclo[3.1.0]-hexane
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic low back pain [ICD-11: MG30.02] | Phase 3 | [1] | |
Neuropathic pain [ICD-11: 8E43.0] | Phase 3 | [1] | ||
Therapeutic Class |
Analgesics
|
|||
Company |
Dov Pharmaceutical
|
|||
Structure |
Download2D MOL |
|||
Formula |
C12H15N
|
|||
Canonical SMILES |
CC1=CC=C(C=C1)C23CC2CNC3
|
|||
InChI |
1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3
|
|||
InChIKey |
OFYVIGTWSQPCLF-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 71195-57-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
8180475, 12015676, 15147197, 33622062, 34712882, 57313166, 79431140, 103585713, 104354237, 126418129, 126684829, 128803524, 131324463, 132554357, 134339221, 134357076, 135047654, 136996475, 137006897, 139258240, 143493258, 152238496, 162121875, 163366968, 170495860, 175426892, 179150997, 223679616, 224051267, 226424261, 241117407, 249808189
|
|||
SuperDrug ATC ID |
L01XX22
|
|||
SuperDrug CAS ID |
cas=005300038
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Norepinephrine transporter (NET) | Target Info | Modulator | [2] |
Serotonin transporter (SERT) | Target Info | Modulator | [2] | |
KEGG Pathway | Serotonergic synapse | |||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
5HT1 type receptor mediated signaling pathway | ||||
5HT2 type receptor mediated signaling pathway | ||||
5HT3 type receptor mediated signaling pathway | ||||
5HT4 type receptor mediated signaling pathway | ||||
Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
WikiPathways | Monoamine Transport | |||
NRF2 pathway | ||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
SIDS Susceptibility Pathways | ||||
Synaptic Vesicle Pathway | ||||
Serotonin Transporter Activity |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||
REF 2 | Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.